Page 1

Novation Holdings Inc Announces Acquisition Of Controlling Interest In Solar Energy Initiatives Inc

9:33am EDT

Novation Holdings Inc announced that it has acquired a controlling interest in Solar Energy Initiatives Inc. in exchange for the stock of HB&G Inc., parent of HB&G Temecula, Inc., which operates a local-themed, entertainment focused, bar and restaurant in Temecula California. The parent, HB&G, Inc. plans to start additional, local themed entertainment restaurants in Southern California, Arizona, Texas and possibly Florida over the next three years. The acquisition was in exchange for a combination of SNRY common stock and a convertible preferred stock with voting power equal to 51% of all voting stock of SNRY. Although originally announced in April, 2013, the final closing and transfer could not be completed until certain open issues with the restaurant's landlord were resolved, which has just been done. Terms of the transaction were not disclosed.

Shanghai RAAS Blood Products Co Ltd to Issue New Shares for Acquisition of Company and Fund Raising

Monday, 1 Jul 2013 08:00pm EDT

Shanghai RAAS Blood Products Co Ltd announced that it has decided to issue a total of 93,652,444 shares, at the price of RMB 19.22 per share, to acquire a 100% stake in Banghe Pharmaceutical Co., Ltd, including 29,191,467 shares to Nanchang-based investment company for a 31.17% stake in Banghe Pharmaceutical, 29,809,573 shares to a Xinjiang-based investment company for a 31.83% stake in Banghe Pharmaceutical, 29,968,782 shares to Mr. Fu Jianping for a 32.00% stake in Banghe Pharmaceutical, as well as 4,682,622 shares to Xiao Xiangyang for a 5.00% stake in Banghe Pharmaceutical. After the transaction, the Company will hold a 100% stake in Banghe Pharmaceutical. The Company has also decided to issue 26,000,000 shares to RAAS China Limited through private placement, at the price of RMB 19.22 per share, to raise RMB 499,720,000. The Company will use the proceeds to develop Banghe Pharmaceutical's main business, as well as fulfill the Company's working capital.

Pfizer Inc, Novartis AG May Join Amgen In Bidding For Onyx Pharmaceuticals Inc-Reuters

Monday, 1 Jul 2013 06:37pm EDT

Reuters reported that Onyx Pharmaceuticals Inc whose cancer drugs promise a strong revenue stream, is attracting preliminary buyout interest from several large pharmaceutical companies such as Pfizer Inc and Novartis AG. Onyx had rejected a recent $8.7 billion offer from larger biotech Amgen Inc as too low. Pfizer, which is due to pay Onyx royalties on a promising experimental breast cancer drug, and Novartis, with a strong franchise of cancer medicines, are among the parties interested in Onyx and its portfolio of marketed cancer treatments, the two sources said. Amgen's $120-per-share offer in June was its first and the company did not indicate if it was the best and final, according to a third person familiar with the matter, who expected Amgen to participate in the auction process. The offer represented a 38% premium to Onyx's Friday closing share price of $86.82.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Energy -0.01%
Basic Materials -0.88%
Industrials -0.61%
Cyclical Goods & Services +0.03%
Non-Cyclical Goods & Services -0.23%
Financials -0.23%
Healthcare -0.43%
Technology +0.04%
Telecoms +0.08%
Utilities -0.64%

Market News

» More News

Analyst Research

Report Title Price
BYOTROL - STILL BUILDING
Provider: Edison Investment Research
$10.00
Buy
BYOTROL - CONSUMER MOVES
Provider: Edison Investment Research
$10.00
Buy
SUMMIT CORPORATION - SERVICE EXPANSION
Provider: Edison Investment Research
$10.00
Buy
LIPOXEN - TRIAL PLANS CONFIRMED
Provider: Edison Investment Research
$10.00
Buy
BYOTROL - REVENUES SHORT OF TARGETS
Provider: Edison Investment Research
$10.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.